[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Lo.Li.Pharma s.r.l\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":126},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,73,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100612760","local-treatment-of-breast-pain-based-on-the-daily-use-of-a-topical-gel-100612760",false,"NCT07257770","Local Treatment of Breast Pain Based on the Daily Use of a Topical Gel","Evaluating the Effect of a Medical Device Based on Inositol in Improving Breast Pain","Inclusion Criteria:\n\n* Women aged between 18 and 70 years\n* Women who underwent breast surgery at least 15 days prior\n* Women experiencing breast pain associated with the surgical wound\n\nExclusion Criteria:\n\n* Women under the age of 18\n* Ongoing systemic and\u002For local pain therapy\n* Pregnant women","FEMALE","18 Years","70 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","The trial aims to investigate the effect of a topical application of a medical device based on inositol in recovering breast pain",[27],"Mastalgia",[29,30,31],"inositol","breast pain","mastalgia","RECRUITING","2026-02-12",{"date":35,"type":36},"2026-02-13","ACTUAL",{"date":38,"type":36},"2025-09-11",{"date":40,"type":21},"2026-07-11",{"name":42,"class":43},"Lo.Li.Pharma s.r.l","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100473705","vitamin-d-epigallocatechin-gallate-d-chiro-inositol-and-vitamin-b6-in-uterine-fibroid-100473705","NCT05448365","Vitamin D, Epigallocatechin Gallate, D-chiro-inositol and Vitamin B6 in Uterine Fibroid","The Use of Vitamin D in Combination With Epigallocatechin Gallate, D-chiro-inositol and Vitamin B6 in the Treatment of Women With Uterine Fibroid","Inclusion Criteria:\n\n1. uterine fibroid with diameter greater than or equal to 4cm or multiple fibroids\n2. eligible for surgery\n3. symptoms like menometrorrhagia or pelvic pain\n\nExclusion Criteria:\n\n1. BMI\\>30\n2. currently pregnant or breastfeeding\n3. diabetic\n4. suspect of malignancy\n5. diagnosis of cancer","30 Years","40 Years",{"count":55,"type":21},60,[24],"The study will evaluate the impact on uterine fibroids' volume of a combination of natural molecules including Epigallocatechin gallate, Vitamin D, D-chiro-inositol and Vitamin B6.\n\nThe patients will be evaluated at baseline and after three months of treatment with placebo or product.",[59,60,61,62,63,64],"Uterine Fibroids","D-chiro-inositol","Inositol","Epigallocatechin Gallate","Vitamin D","Vitamin B6","2026-02-10",{"date":33,"type":36},{"date":68,"type":36},"2022-07-01",{"date":70,"type":21},"2026-07-01",{"name":42,"class":43},2,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},"100577582","treatment-of-menstrual-cycle-alterations-in-adolescents-100577582","NCT06800170","Treatment of Menstrual Cycle Alterations in Adolescents","HP-phD_Adolesc","Inclusion Criteria:\n\n* adolescent women aged 14-19 years old, with at least 3 years passed after menarche, and oligomenorrhea or amenorrhea\n\nExclusion Criteria:\n\n* Primary amenorrhea.\n* Hyperandrogenism due to other factors (i.e. adrenal hyperplasia or Cushing syndrome).\n* Hyperprolactinemia or overt hypothyroidism (TSH ≥4).\n* Other hormonal alterations.\n* Ongoing hormonal therapies, including OCPs, six months before enrollment.\n* Ongoing pharmacological therapies.\n* Ongoing use of myo-Inositol supplement or other source of myo-Inositol, or Dioscorea villosa, six months before enrollment.","14 Years","19 Years",{"count":83,"type":21},20,[24],"the aim of the present study is intended to evaluate how treatment with Myo-Inositol and Dioscorea Villosa can help improve menstrual cycle irregularities in adolescents, both with and without PCOS.",[87,88,89],"Amenorrhea","Oligomenorrhea","PCOS (Polycystic Ovary Syndrome)",[91,92,93],"myo-Inositol","Dioscorea Villosa","adolescents","2026-01-05",{"date":96,"type":36},"2026-01-06",{"date":98,"type":36},"2025-06-01",{"date":100,"type":21},"2026-12",{"name":42,"class":43},3,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":44},"100538017","the-effect-of-the-association-egcg-folic-acid-and-vitamin-b12-in-preventing-the-persistence-of-hpv-infection-100538017","NCT06285357","The Effect of the Association EGCG, Folic Acid and Vitamin B12 in Preventing the Persistence of HPV Infection.","A Pilot Study to Test the Effect of the Association of Epigallocatechin Gallate (EGCG), Folic Acid and Vitamin B12 in Preventing the Persistence of Human Papilloma Virus (HPV) Infection.","Inclusion Criteria:\n\n* HR-HPV DNA test positivity\n\nExclusion Criteria:\n\n* No HSIL","25 Years","65 Years",{"count":113,"type":21},100,[24],"The purpose of the study is to test the effect of the administration of a dietary supplement consisting of epigallocatechin gallate (EGCG), vitamin B12 and folic acid in the treatment of infections with papilloma virus of the cervix.",[117],"HPV Infection","2025-11-19",{"date":120,"type":36},"2025-11-20",{"date":122,"type":36},"2024-02-19",{"date":124,"type":21},"2026-08",{"name":42,"class":43},""]